EyePoint Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 121
- Market Cap
- $486.4M
- Introduction
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Clinical Trials
17
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
LUCIA: A Phase 3 randomized, double-masked study comparing the efficacy of EYP-1901 against aflibercept
- Conditions
- Wet age-related macular degeneration (wAMD)
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Eyepoint Pharmaceuticals Inc.
- Target Recruit Count
- 143
- Registration Number
- 2024-518030-83-00
- Locations
- 🇺🇸
Associated Retina Consultans, Gilbert, Arizona, United States
🇺🇸Associated Retina Consultants - Phoenix, Phoenix, Arizona, United States
🇺🇸Phoenix Retina Clinical Trials, LLC, Phoenix, Arizona, United States
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
- Conditions
- Wet Age Related Macular DegenerationwAMD
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06668064
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Retina Partners of Northwest Arkansas, Springdale, Arkansas, United States
🇺🇸California Retina Consultants, Bakersfield, California, United States
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06099184
- Locations
- 🇺🇸
EyePoint Investigative Site, Lynchburg, Virginia, United States
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
- Conditions
- Cataract
- Interventions
- Drug: DexycuOther: Placebo/Vehicle
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05550350
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
- Conditions
- Cataract
- Interventions
- Other: Placebo/VehicleDrug: Dexycu
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- EyePoint Pharmaceuticals, Inc.
- Registration Number
- NCT05550363
- Prev
- 1
- 2
- 3
- 4
- Next